Bernadus Winata - Kalbe Farma Independent Director, Corporate Secretary
| KLBF Stock | IDR 1,415 40.00 2.75% |
Director
Mr. Bernadus Karmin Winata serves as Independent Director, Corporationrationrate Secretary of PT Kalbe Farma Tbk since June 14, 2017. He was appointed as Company Independent Director on June 5, 2017. He graduated a degree in Accountancy from Universitas Padjadjaran in 1988. since 2017.
| Age | 52 |
| Tenure | 7 years |
| Phone | 62 21 4287 3888 |
| Web | https://www.kalbe.co.id |
Kalbe Farma Management Efficiency
The company has return on total asset (ROA) of 0.106 % which means that it generated a profit of $0.106 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1673 %, meaning that it generated $0.1673 on every $100 dollars invested by stockholders. Kalbe Farma's management efficiency ratios could be used to measure how well Kalbe Farma manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 532.51 B in total debt. Debt can assist Kalbe Farma until it has trouble settling it off, either with new capital or with free cash flow. So, Kalbe Farma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kalbe Farma Tbk sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kalbe to invest in growth at high rates of return. When we think about Kalbe Farma's use of debt, we should always consider it together with cash and equity.
Kalbe Farma Tbk (KLBF) is traded on Jakarta Exchange in Indonesia and employs 12,644 people. Management Performance
| Return On Equity | 0.17 | |||
| Return On Asset | 0.11 |
Kalbe Farma Tbk Leadership Team
Elected by the shareholders, the Kalbe Farma's board of directors comprises two types of representatives: Kalbe Farma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kalbe. The board's role is to monitor Kalbe Farma's management team and ensure that shareholders' interests are well served. Kalbe Farma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kalbe Farma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Djonny Tjahyadi, Director | ||
| Lanny Soputro, G HR | ||
| Ferdinand Aryanto, Commissioner | ||
| Santoso Oen, Commissioner | ||
| Ongkie Tedjasurja, Director | ||
| Sie Djohan, Management Devel | ||
| Bernadus Winata, Independent Director, Corporate Secretary | ||
| Johannes Setijono, President Commissioner | ||
| Bujung Nugroho, Director | ||
| Vidjongtius, Director, Corporate Secretary, IR Contact Officer | ||
| Lucky Slamet, Independent Commissioner | ||
| Farid Moeloek, Independent Commissioner | ||
| Kurniawan Suhartono, Head Unit | ||
| Bernadette Setiady, President Director | ||
| Lilis Halim, Independent Commissioner | ||
| Johanes Ibrahim, Independent Commissioner | ||
| Ronny Hadiana, Commissioner | ||
| Lukito Gozali, Head Relations |
Kalbe Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kalbe Farma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.17 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 95.3 T | |||
| Shares Outstanding | 46.26 B | |||
| Shares Owned By Insiders | 58.08 % | |||
| Shares Owned By Institutions | 15.23 % | |||
| Price To Book | 5.06 X | |||
| Price To Sales | 3.36 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Kalbe Stock analysis
When running Kalbe Farma's price analysis, check to measure Kalbe Farma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalbe Farma is operating at the current time. Most of Kalbe Farma's value examination focuses on studying past and present price action to predict the probability of Kalbe Farma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalbe Farma's price. Additionally, you may evaluate how the addition of Kalbe Farma to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |